Alzheimer's disease patients who took cholinesterase inhibitors to improve cognitive function were 34% less likely to die and experience myocardial infarction than non-users, researchers found. The risk of myocardial infarction was lowest among those who took the highest doses. The study, based on data from more than 7,000 patients in Sweden, was published in the European Heart Journal.

Related Summaries